Chemical compounds
The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
1. 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide of formula (I);
or a pharmaceutically acceptable salt thereof.
2. 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide of formula (I)
3. A pharmaceutical composition comprising (a) 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide or a pharmaceutically acceptable salt thereof, and (b) one or more pharmaceutically acceptable excipients.
4. A pharmaceutical composition according to claim 3 , which further comprises one or more additional pharmaceutically active compounds.
5. A method of treating a disorder mediated by inappropriate IKK2 activity comprising administering a safe and effective amount of 3-[1 (ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide, or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the disorder mediated by inappropriate IKK2 activity is asthma or COPD.
6. The method of claim 5 , wherein the disorder mediated by inappropriate IKK2 activity is asthma.
7. The method of claim 5 , wherein the disorder mediated by inappropriate IKK2 activity is COPD.